Published in Gut on August 01, 1991
Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification. Gut (1999) 7.14
Predictive factors of the long term outcome in gastro-oesophageal reflux disease: six year follow up of 107 patients. Gut (1994) 1.33
Natural history of reflux oesophagitis: a 10 year follow up of its effect on patient symptomatology and quality of life. Gut (1996) 1.28
Effect of famotidine on oesophageal sensitivity in gastro-oesophageal reflux disease. Gut (1994) 1.21
Associations between different forms of gastro-oesophageal reflux disease. Gut (1997) 1.21
NERD: an umbrella term including heterogeneous subpopulations. Nat Rev Gastroenterol Hepatol (2013) 1.20
The effect of metabolic risk factors on the natural course of gastro-oesophageal reflux disease. Gut (2008) 1.18
Nonerosive Reflux Disease (NERD) - An Update. J Neurogastroenterol Motil (2010) 1.04
Influence of lumbar kyphosis and back muscle strength on the symptoms of gastroesophageal reflux disease in middle-aged and elderly people. Eur Spine J (2012) 0.87
Nonerosive gastroesophageal reflux disease and mild degree of esophagitis: comparison of symptoms endoscopic, manometric and pH-metric patterns. World J Surg Oncol (2012) 0.80
Heterogeneity of endoscopy negative heartburn: epidemiology and natural history. World J Gastroenterol (2008) 0.79
Evaluating outcomes of endoscopic full-thickness plication for gastroesophageal reflux disease (GERD) with impedance monitoring. Surg Endosc (2009) 0.78
Functional Gastroesophageal Reflux Disease (GERD). Curr Treat Options Gastroenterol (2000) 0.77
Bleeding and stenosis caused by reflux esophagitis was not common in emergency endoscopic examinations: a retrospective patient chart review at a single institution in Japan. J Gastroenterol (2008) 0.75
Outcome of nonerosive gastro-esophageal reflux disease patients with pathological acid exposure. World J Gastroenterol (2009) 0.75
Gastroesophageal reflux. Pathogenesis, diagnosis, and therapy. Ann Intern Med (1982) 2.63
Healing and relapse of reflux esophagitis during treatment with ranitidine. Gastroenterology (1986) 2.02
Optimal thresholds, sensitivity, and specificity of long-term pH-metry for the detection of gastroesophageal reflux disease. Gastroenterology (1987) 1.88
Medical therapy for chronic reflux esophagitis. Long-term follow-up. Arch Intern Med (1987) 1.67
Medical and surgical management of reflux esophagitis. A 38-month report of a prospective clinical trial. N Engl J Med (1975) 1.49
Epidemiology of oesophageal reflux disease. Scand J Gastroenterol Suppl (1989) 1.20
Domperidone, metoclopramide, and placebo. All give symptomatic improvement in gastroesophageal reflux. J Clin Gastroenterol (1986) 1.01
Pattern of acid reflux in patients with reflux esophagitis 'resistant' to H2-receptor antagonists. Scand J Gastroenterol (1990) 0.92
Short and long-term effect of two different dosages of ranitidine in the therapy of reflux oesophagitis. Ital J Gastroenterol (1990) 0.90
Systematic review: gastro-oesophageal reflux disease and dental lesions. Aliment Pharmacol Ther (2008) 2.56
Gastroscopic evaluation of anti-inflammatory agents. Br Med J (1980) 2.51
Gastroscopy in elderly patients. Curr Med Res Opin (1982) 1.89
Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis. Gut (2005) 1.84
Current European concepts in the management of Helicobacter pylori infection--the Maastricht Consensus Report. The European Helicobacter Pylori Study Group (EHPSG). Eur J Gastroenterol Hepatol (1997) 1.81
Factors affecting splanchnic haemodynamics in Crohn's disease: a prospective controlled study using Doppler ultrasound. Gut (1998) 1.64
Comparison between methotrexate and azathioprine in the treatment of chronic active Crohn's disease: a randomised, investigator-blind study. Dig Liver Dis (2003) 1.61
Multiple ulcerative esophagitis caused by alendronate. Am J Gastroenterol (1995) 1.60
A comparison of two different doses of omeprazole versus ranitidine in treatment of duodenal ulcers. J Clin Gastroenterol (1986) 1.46
Oral and topical 5-aminosalicylic acid (mesalazine) in inducing and maintaining remission in mild-moderate relapse of ulcerative colitis: one-year randomised multicentre trial. Dig Liver Dis (2002) 1.44
Helicobacter pylori CagA seropositivity does not influence inflammatory parameters, lipid concentrations and haemostatic factors in healthy individuals. J Intern Med (2000) 1.44
Treatment of cytomegalovirus esophagitis in patients with acquired immune deficiency syndrome: a randomized controlled study of foscarnet versus ganciclovir. The Italian Cytomegalovirus Study Group. Am J Gastroenterol (1998) 1.43
Mesalazine foam (Salofalk foam) in the treatment of active distal ulcerative colitis. A comparative trial vs Salofalk enema. The SAF-3 study group. Ital J Gastroenterol Hepatol (1999) 1.42
Hospital use of acid-suppressive medications and its fall-out on prescribing in general practice: a 1-month survey. Aliment Pharmacol Ther (2003) 1.40
Helicobacter pylori eradication in the healing and recurrence of benign gastric ulcer: a two-year, double-blind, placebo controlled study. Ital J Gastroenterol Hepatol (1997) 1.40
The watermelon stomach: clinical, endoscopic, endosonographic, and therapeutic aspects in three cases. Endoscopy (1995) 1.40
Sucralfate and hydrocortisone enemas in the treatment of active ulcerative proctitis--a randomized single-blind comparative study. Aliment Pharmacol Ther (1996) 1.39
Prolonging proton pump inhibitor-based anti-Helicobacter pylori treatment from one to two weeks in duodenal ulcer: is it worthwhile? Dig Liver Dis (2000) 1.39
Pretreatment endoscopy--pro & contra: endoscopy is needed before treatment in all patients with gastroesophageal reflux disease. Endoscopy (2006) 1.38
Nonspecific inflammatory bowel disease and smoking. Am J Epidemiol (1987) 1.34
Abdominal ultrasound in the assessment of extent and activity of Crohn's disease: clinical significance and implication of bowel wall thickening. Am J Gastroenterol (1996) 1.33
Ultrasonographic detection of intestinal complications in Crohn's disease. Dig Dis Sci (1996) 1.25
Altered bone metabolism in inflammatory bowel disease: there is a difference between Crohn's disease and ulcerative colitis. J Intern Med (2000) 1.24
Inflammatory bowel disease: new insights into pathogenesis and treatment. J Intern Med (2002) 1.23
Cigarette smoking, gastric acid secretion, and serum pepsinogen I concentrations in duodenal ulcer patients. Gut (1985) 1.20
Prevalence and clinical features of heterotopic gastric mucosa in the upper oesophagus (inlet patch). Eur J Gastroenterol Hepatol (2000) 1.12
Treatment of refractory peptic ulcer with omeprazole or continued H2 receptor antagonists: a controlled clinical trial. Gut (1991) 1.11
Campylobacter pylori and ulcer recurrence. Lancet (1988) 1.11
Preparation, premedication and surveillance. Endoscopy (2003) 1.07
Preparation, premedication, and surveillance. Endoscopy (2005) 1.07
Do some patients with Helicobacter pylori infection benefit from an extension to 2 weeks of a proton pump inhibitor-based triple eradication therapy? Am J Gastroenterol (2001) 1.07
Role of early ultrasound in detecting inflammatory intestinal disorders and identifying their anatomical location within the bowel. Aliment Pharmacol Ther (2003) 1.06
Inflammatory bowel disease versus irritable bowel syndrome: a hospital-based, case-control study of disease impact on quality of life. Scand J Gastroenterol (2003) 1.06
Focal gastric inflammatory infiltrates in inflammatory bowel diseases: prevalence, immunohistochemical characteristics, and diagnostic role. Am J Gastroenterol (2000) 1.05
Kaposi's sarcoma and AIDS: frequency of gastrointestinal involvement and its effect on survival. A prospective study in a heterogeneous population. Scand J Gastroenterol (1991) 1.03
Cerebral metabolism after portacaval shunt. Lancet (1969) 1.03
Quality of life during acute and intermittent treatment of gastro-oesophageal reflux disease with omeprazole compared with ranitidine. Results from a multicentre clinical trial. The European Study Group. Ital J Gastroenterol Hepatol (1998) 1.03
Relapse rates in duodenal ulcer patients formerly treated with bismuth subcitrate or maintained with cimetidine. Lancet (1984) 1.03
Small bowel stenosis in Crohn's disease: clinical, biochemical and ultrasonographic evaluation of histological features. Aliment Pharmacol Ther (2003) 1.02
Prevalence, detection rate and outcome of cytomegalovirus infection in ulcerative colitis patients requiring colonic resection. Dig Liver Dis (2005) 1.02
Effects of eradication of Helicobacter pylori on gastritis in duodenal ulcer patients. Scand J Gastroenterol Suppl (1994) 1.01
Mesalamine in the treatment of mild to moderate active Crohn's ileitis: results of a randomized, multicenter trial. Gastroenterology (1999) 1.01
Treatment options for patients with Helicobacter pylori infection resistant to one or more eradication attempts. Dig Liver Dis (2003) 1.01
Multidrug resistance 1 gene polymorphism and susceptibility to inflammatory bowel disease. Inflamm Bowel Dis (2007) 0.99
Pirenzepine in the treatment of peptic ulcer disease. Review and commentary. Scand J Gastroenterol Suppl (1982) 0.97
Description of new "bowel-sparing" techniques for long strictures of Crohn's disease. Am J Surg (1997) 0.97
Is maintenance therapy always necessary for patients with ulcerative colitis in remission? Aliment Pharmacol Ther (1999) 0.96
Medium-dose antacids versus cimetidine in the short-term treatment of duodenal ulcer. J Clin Gastroenterol (1986) 0.96
Prevalence of Helicobacter pylori infection and related upper gastrointestinal lesions in patients with inflammatory bowel diseases. A cross-sectional study with matching. Scand J Gastroenterol (1997) 0.96
Natural history of gastro-oesophageal reflux disease without oesophagitis (NERD)--a reappraisal 10 years on. Dig Liver Dis (2004) 0.96
Discordance between the degree of osteopenia and the prevalence of spontaneous vertebral fractures in Crohn's disease. Aliment Pharmacol Ther (2002) 0.95
Immunomodulatory effects of 1,25-dihydroxyvitamin D3 on TH1/TH2 cytokines in inflammatory bowel disease: an in vitro study. Int J Immunopathol Pharmacol (2009) 0.95
Is interferon-alpha therapy safe and effective for patients with chronic hepatitis C and inflammatory bowel disease? A case-control study. Aliment Pharmacol Ther (2005) 0.95
Opportunistic infections of the esophagus not responding to oral systemic antifungals in patients with AIDS: their frequency and treatment. Am J Gastroenterol (1991) 0.95
Ultrasonography in the evaluation of extension, activity, and follow-up of ulcerative colitis. Scand J Gastroenterol (1999) 0.94
Long-term results and multivariate analysis of prognostic factors in 138 consecutive patients operated on for Crohn's disease using "bowel-sparing" techniques. Am J Surg (2000) 0.94
Treatment of morbid obesity by intraparietogastric administration of botulinum toxin: a randomized, double-blind, controlled study. Int J Obes (Lond) (2006) 0.93
A practical guide to the management of distal ulcerative colitis. Drugs (1998) 0.93
Gastrointestinal side-effects of traditional non-steroidal anti-inflammatory drugs and new formulations. Aliment Pharmacol Ther (2004) 0.93
Placebo controlled studies with ranitidine in duodenal ulcer. Scand J Gastroenterol Suppl (1981) 0.92
Transient small-bowel intussusceptions in adults: significance of ultrasonographic detection. Clin Radiol (2007) 0.92
Management of Helicobacter pylori-related gastrointestinal diseases by general practitioners in Italy. Aliment Pharmacol Ther (1999) 0.91
Effect of Helicobacter pylori eradication on gastric histology, serum gastrin and pepsinogen I levels, and gastric emptying in patients with gastric ulcer. Am J Gastroenterol (1997) 0.91
Long-term low-dose antacid versus cimetidine therapy in the treatment of duodenal ulcer recurrence. Scand J Gastroenterol (1986) 0.91
Efficacy and tolerability of polyethylene glycol-electrolyte lavage solution with and without simethicone in the preparation of patients with inflammatory bowel disease for colonoscopy. Aliment Pharmacol Ther (1993) 0.91
Serodiagnosis of Helicobacter pylori-associated gastritis with a monoclonal antibody competitive enzyme-linked immunosorbent assay. Scand J Gastroenterol (1992) 0.91
Gastroesophageal reflux disease: a typical spectrum disease (a new conceptual framework is not needed). Am J Gastroenterol (2004) 0.91
Azathioprine in steroid-resistant and steroid-dependent ulcerative colitis. J Clin Gastroenterol (1997) 0.90
Short and long-term effect of two different dosages of ranitidine in the therapy of reflux oesophagitis. Ital J Gastroenterol (1990) 0.90
Levosulpiride in functional dyspepsia: a multicentric, double-blind, controlled trial. Ital J Gastroenterol (1997) 0.90
The (13)C-urea breath test for non-invasive diagnosis of Helicobacter pylori infection: which procedure and which measuring equipment? Eur J Gastroenterol Hepatol (2001) 0.90
The vascularity of internal fistulae in Crohn's disease: an in vivo power Doppler ultrasonography assessment. Gut (2002) 0.90
Cisapride versus placebo in reflux esophagitis. A multicenter double-blind trial. J Clin Gastroenterol (1988) 0.89
Helicobacter pylori infection and coagulation in healthy people. BMJ (1997) 0.89
Women and duodenal ulcer. Br Med J (Clin Res Ed) (1981) 0.88
Doppler ultrasound measurement of intestinal blood flow in inflammatory bowel disease. Scand J Gastroenterol (1996) 0.88
Cerebral blood flow and metabolism in hepatic cirrhosis before and after portacaval shunt operation. Gut (1969) 0.88
Stool test with polyclonal antibodies for monitoring Helicobacter pylori eradication in adults: a critical reappraisal. Scand J Gastroenterol (2002) 0.87
Different effects of short-term omeprazole, lansoprazole or pantoprazole on the accuracy of the (13)C-urea breath test. Aliment Pharmacol Ther (2002) 0.87
Prevention of symptomatic recurrences of esophageal candidiasis in AIDS patients after the first episode: a prospective open study. Am J Gastroenterol (1994) 0.87
Gastric cancer in young patients with no alarm symptoms: focus on delay in diagnosis, stage of neoplasm and survival. Scand J Gastroenterol (2003) 0.86
Preoperative characteristics and postoperative behavior of bowel wall on risk of recurrence after conservative surgery in Crohn's disease: a prospective study. Ann Surg (2001) 0.86
A double-blind endoscopic study with De-Nol tablets and cimetidine for duodenal ulcer. Scand J Gastroenterol (1984) 0.86
Prophylaxis and treatment of non-steroidal anti-inflammatory drug-induced upper gastrointestinal side-effects. Dig Liver Dis (2001) 0.86
Preparation, premedication and surveillance. Endoscopy (1998) 0.85
The effect of intravenous doxofylline or aminophylline on gastric secretion in duodenal ulcer patients. Aliment Pharmacol Ther (1990) 0.85
Treatment of Helicobacter pylori infection. Indications and regimens: an update. Dig Liver Dis (2002) 0.85
Preparation, premedication, and surveillance. Endoscopy (2001) 0.84
Somatostatin and cimetidine in the control of acute upper gastrointestinal bleeding. A controlled multicenter study. Hepatogastroenterology (1986) 0.84
Effects of magnesium-aluminum hydroxide antacid on absorption of rufloxacin. Antimicrob Agents Chemother (1993) 0.84
Effect of cisapride on gastric emptying and ileal transit time of balanced liquid meal in healthy subjects. Digestion (1987) 0.84
Autoantibody profile during short-term infliximab treatment for Crohn's disease: a prospective cohort study. Aliment Pharmacol Ther (2005) 0.84
Treatment of Helicobacter pylori infection using a novel antiadhesion compound (3'sialyllactose sodium salt). A double blind, placebo-controlled clinical study. Helicobacter (2003) 0.84
Mesalazine (5-aminosalicylic acid) suppositories in the treatment of ulcerative proctitis or distal proctosigmoiditis. A randomized controlled trial. Scand J Gastroenterol (1990) 0.84